OncoTICE 12.5mg (Bcg Ampoules) 12.5mg

OncoTICE 12.5mg is a BCG immunotherapy used for bladder cancer treatment. This 12.5mg ampoule form contains live attenuated Mycobacterium bovis for intravesical therapy. Store between 2-8°C to maintain potency. Always follow healthcare provider instructions for use.

Strength

12.5mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Merck Sharp & Dohme UK Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

OncoTICE 12.5mg is used as a bladder cancer treatment through intravesical immunotherapy. It works by stimulating the immune system to target cancer cells in the bladder. This medication is specifically indicated for carcinoma in situ and to prevent recurrence of superficial bladder cancer. Patients often ask what is BCG used for in cancer treatment.

Side Effects

OncoTICE 12.5mg may cause flu-like symptoms such as fever, chills, or fatigue after administration. Some patients experience bladder irritation or urinary urgency following treatment. These effects are typically temporary and part of the immune response stimulation. Most reactions resolve within a few days of treatment.

Precautions & Warnings

Handle OncoTICE 12.5mg ampoules with care to avoid contamination or spillage. Keep refrigerated between 2-8°C and protect from light. Do not freeze or shake vigorously. Use within specified time after reconstitution as directed by healthcare professional. Avoid contact with skin or mucous membranes during preparation.

Avoid Interactions

OncoTICE 12.5mg may interact with immune-suppressing medications like corticosteroids. Antibiotics might reduce its effectiveness if taken concurrently. Patients should inform their doctor about all medications, including over-the-counter products. Live vaccines may interact with BCG therapy; discuss timing with healthcare provider.

Frequently Asked Questions

OncoTICE 12.5mg is a BCG immunotherapy used to treat bladder cancer and prevent recurrence.

It is administered directly into the bladder through a catheter as intravesical therapy.

Common effects include flu-like symptoms, bladder irritation, and urinary urgency.

Pregnant individuals should avoid handling BCG medications due to potential risks.

Store between 2-8°C and use within the timeframe specified after reconstitution.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.